Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 3, 2025

Purified anti-human CD38 (Maxpar(R) Ready)

RRID:AB_2562819 Type: Antibody

Proper Citation

(BioLegend Cat# 303535, RRID:AB_2562819)

Antibody Information

URL: http://antibodyregistry.org/AB_2562819

Proper Citation: (BioLegend Cat# 303535, RRID:AB_2562819)

Target Antigen: CD38

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC, CyTOF®

Antibody Name: Purified anti-human CD38 (Maxpar(R) Ready)

Description: This monoclonal targets CD38

Target Organism: human

Clone ID: Clone HIT2

Antibody ID: AB_2562819

Vendor: BioLegend

Catalog Number: 303535

Record Creation Time: 20231110T035220+0000

Record Last Update: 20240724T232717+0000

Ratings and Alerts

No rating or validation information has been found for Purified anti-human CD38 (Maxpar(R) Ready).

No alerts have been found for Purified anti-human CD38 (Maxpar(R) Ready).

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 8 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Klysz DD, et al. (2024) Inosine induces stemness features in CAR-T cells and enhances potency. Cancer cell, 42(2), 266.

Gerassy-Vainberg S, et al. (2024) A personalized network framework reveals predictive axis of anti-TNF response across diseases. Cell reports. Medicine, 5(1), 101300.

Kaczanowska S, et al. (2024) Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy. Cancer cell, 42(1), 35.

Yousuf S, et al. (2023) Spatially Resolved Multi-Omics Single-Cell Analyses Inform Mechanisms of Immune Dysfunction in Pancreatic Cancer. Gastroenterology, 165(4), 891.

van der Sluis TC, et al. (2023) OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell reports. Medicine, 4(3), 100939.

, et al. (2022) A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell, 185(5), 916.

Labanieh L, et al. (2022) Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell, 185(10), 1745.

McIlwain DR, et al. (2021) Human influenza virus challenge identifies cellular correlates of protection for oral vaccination. Cell host & microbe, 29(12), 1828.